← Back to All US Stocks

ADGM Stock Analysis - Adagio Medical Holdings, Inc. AI Rating

ADGM Nasdaq Surgical & Medical Instruments & Apparatus DE CIK: 0002006986
Analysis Date: Mar 19, 2026 | Data as of: 2025-09-30
AI Rating
STRONG SELL
95% Confidence

Investment Thesis

Adagio Medical is in severe financial distress with zero revenue, negative stockholders' equity of -$1.3M, and substantial operating losses of -$17.8M. The company is burning cash at an unsustainable rate with negative free cash flow of -$15.7M, while carrying $21.2M in long-term debt against only $4.7M in cash, indicating imminent liquidity crisis.

ADGM Strengths

  • + Maintains $4.7M cash position providing short-term runway
  • + Medical device sector has growth potential if company survives
  • + Recent insider activity suggests management engagement despite challenges

ADGM Risks

  • ! Zero revenue indicates complete failure to commercialize products or generate market acceptance
  • ! Negative stockholders' equity of -$1.3M represents technical insolvency
  • ! Negative free cash flow of -$15.7M with only $4.7M cash means 3-4 months of runway at current burn rate
  • ! Current ratio of 0.84x and quick ratio of 0.68x indicate inability to meet short-term obligations
  • ! $21.2M long-term debt burden with no revenue stream to service debt
  • ! ROA of -69% demonstrates severe asset inefficiency and value destruction

Key Metrics to Watch

ADGM Financial Metrics

Revenue
$0.0
Net Income
$-21.8M
EPS (Diluted)
$-1.42
Free Cash Flow
$-15.7M
Total Assets
$31.5M
Cash Position
$4.7M

ADGM Profitability Ratios

Gross Margin N/A
Operating Margin N/A
Net Margin N/A
ROE N/A
ROA -69.0%
FCF Margin N/A

ADGM Balance Sheet & Liquidity

Current Ratio
0.84x
Quick Ratio
0.68x
Debt/Equity
N/A
Debt/Assets
104.2%
Interest Coverage
N/A
Long-term Debt
$21.2M

ADGM 5-Year Financial Trend

ADGM 5-year financial data: Year 2024: Revenue $333.0K, Net Income -$36.6M, EPS $-48.16.
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: Adagio Medical Holdings, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-48.16 indicates the company is currently unprofitable.

ADGM Growth Metrics (YoY)

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
N/A
Free cash flow / Revenue

ADGM Quarterly Performance

Quarterly financial performance data for Adagio Medical Holdings, Inc. including revenue, net income, and earnings per share.
Quarter Revenue Net Income EPS
Q3 2025 N/A $3.6M $0.02
Q2 2025 $254.0K -$3.9M $-0.35
Q1 2025 $26.0K -$7.7M $-0.51
Q3 2024 $41.0K $3.6M $0.02

Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.

ADGM Capital Allocation

Operating Cash Flow
-$14.9M
Cash generated from operations
Capital Expenditures
$865.0K
Investment in assets
Dividends
None
No dividend program

ADGM SEC Filings

Access official SEC EDGAR filings for Adagio Medical Holdings, Inc. (CIK: 0002006986)

Disclaimer: This analysis is generated by Claude AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Mar 19, 2026 | Data as of: 2025-09-30 | Powered by Claude AI